Listen
VERKAZIA (ciclosporine)
Reason for request
- Key points
Favourable opinion for reimbursement in the treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents.
- What therapeutic improvement?
Slight therapeutic improvement.
- Role in the care pathway?
The current treatment of VKC defined by the French Society of Ophthalmology (2015) consists, firstly, of rinsing the eye with normal saline, anti-allergy eye drops and local corticosteroids prescribed in the short term due to the risk of glaucoma and cataract.
In severe corticosteroid-dependent forms with corneal complications, topical ciclosporin is the reference option, enabling corticosteroid therapy sparing.
Oral corticosteroids may be necessary in very rare, vision-threatening forms resistant to all other treatments, with a treatment duration that is as short as possible.
Role of the medicinal product in the care pathway
VERKAZIA is a second-line treatment in severe VKC in children and adolescents who have not responded to anti-allergy eye drops and are corticosteroid-dependent.
Clinical Benefit
| Substantial |
The clinical benefit of VERKAZIA 1 mg/ml eye drops, emulsion is substantial in the MA indication.
|
Clinical Added Value
| minor |
VERKAZIA 1 mg/ml eye drops, emulsion provides a minor clinical added value (CAV IV) in the treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents.
|
